gatifloxacin has been researched along with Pyrexia in 3 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gatifloxacin (GA) is an alternative, though it has not been thoroughly studied in Pediatrics yet." | 6.73 | Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. ( Alberto Pires Pereira, C; Altruda Carlesse, F; Petrilli, A, 2007) |
| "Patients with breast cancer or sarcoma who presented with fever and neutropenia and were identified as low risk received empiric, oral, quinolone monotherapy (gatifloxacin at a dose of 400 mg once daily)." | 3.73 | Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. ( Benjamin, RS; Elting, LS; Frisbee-Hume, SE; Manzullo, EF; McMahon, L; Patel, S; Rolston, KV; Theriault, RL, 2006) |
| "Gatifloxacin (GA) is an alternative, though it has not been thoroughly studied in Pediatrics yet." | 2.73 | Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia. ( Alberto Pires Pereira, C; Altruda Carlesse, F; Petrilli, A, 2007) |
| "We found serological evidence of acute murine typhus in 21 of 125 (17%) patients, with 12 of 21 (57%) patients polymerase chain reaction (PCR)-positive for Rickettsia typhi." | 1.42 | Undifferentiated febrile illness in Kathmandu, Nepal. ( Arjyal, A; Baker, S; Basnyat, B; Blacksell, SD; Day, N; Dolecek, C; Dongol, S; Farrar, J; Giri, A; Karkey, A; Paris, DH; Thompson, CN; Thwaites, G, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Thompson, CN | 1 |
| Blacksell, SD | 1 |
| Paris, DH | 1 |
| Arjyal, A | 1 |
| Karkey, A | 1 |
| Dongol, S | 1 |
| Giri, A | 1 |
| Dolecek, C | 1 |
| Day, N | 1 |
| Baker, S | 1 |
| Thwaites, G | 1 |
| Farrar, J | 1 |
| Basnyat, B | 1 |
| Rolston, KV | 1 |
| Manzullo, EF | 1 |
| Elting, LS | 1 |
| Frisbee-Hume, SE | 1 |
| McMahon, L | 1 |
| Theriault, RL | 1 |
| Patel, S | 1 |
| Benjamin, RS | 1 |
| Petrilli, A | 1 |
| Altruda Carlesse, F | 1 |
| Alberto Pires Pereira, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal[NCT02773407] | Phase 3 | 330 participants (Actual) | Interventional | 2016-05-23 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gatifloxacin and Pyrexia
| Article | Year |
|---|---|
Oral gatifloxacin in the outpatient treatment of children with cancer fever and neutropenia.
Topics: Administration, Oral; Adolescent; Adult; Ambulatory Care; Anti-Infective Agents; Antineoplastic Agen | 2007 |
2 other studies available for gatifloxacin and Pyrexia
| Article | Year |
|---|---|
Undifferentiated febrile illness in Kathmandu, Nepal.
Topics: Anti-Bacterial Agents; Fever; Fluoroquinolones; Gatifloxacin; Humans; Nepal; Ofloxacin; Prospective | 2015 |
Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Breast Neoplasms; Feasibi | 2006 |